CS275613B6 - Process for preparing insulin analogs - Google Patents

Process for preparing insulin analogs Download PDF

Info

Publication number: CS275613B6
Authority: CS; Czechoslovakia
Prior art keywords: asp; glu; human insulin; insulin; ala
Prior art date: 1985-08-30

Application number

CS866310A

Other languages

Czech (cs)

English (en)

Other versions

CS8606310A2 (en

Inventor

Jens Jorgen Veilgaard Brange

Kjeld Norris

Mogens Trier Hansen

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-08-30

Filing date

1986-08-29

Publication date

1992-03-18

1985-08-30 Priority claimed from DK395685A external-priority patent/DK395685D0/da

1985-10-14 Priority claimed from DK467785A external-priority patent/DK467785D0/da

1986-08-29 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1990-09-12 Publication of CS8606310A2 publication Critical patent/CS8606310A2/cs

1992-03-18 Publication of CS275613B6 publication Critical patent/CS275613B6/cs

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 176
238000004519 manufacturing process Methods 0.000 title description 10
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims abstract description 76
101000976075 Homo sapiens Insulin Proteins 0.000 claims abstract description 53
125000000539 amino acid group Chemical group 0.000 claims abstract description 42
238000002360 preparation method Methods 0.000 claims abstract description 13
150000001413 amino acids Chemical group 0.000 claims abstract description 12
102000004877 Insulin Human genes 0.000 claims description 73
108090001061 Insulin Proteins 0.000 claims description 73
229940125396 insulin Drugs 0.000 claims description 72
238000000034 method Methods 0.000 claims description 37
239000002243 precursor Substances 0.000 claims description 34
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 31
239000004026 insulin derivative Substances 0.000 claims description 16
239000004473 Threonine Substances 0.000 claims description 13
229960002898 threonine Drugs 0.000 claims description 13
-1 threonine ester Chemical class 0.000 claims description 13
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 10
102000004142 Trypsin Human genes 0.000 claims description 9
108090000631 Trypsin Proteins 0.000 claims description 9
229940024606 amino acid Drugs 0.000 claims description 9
239000012588 trypsin Substances 0.000 claims description 9
238000006243 chemical reaction Methods 0.000 claims description 8
230000007062 hydrolysis Effects 0.000 claims description 5
238000006460 hydrolysis reaction Methods 0.000 claims description 5
108090000765 processed proteins & peptides Proteins 0.000 claims description 5
239000011541 reaction mixture Substances 0.000 claims description 5
IASQBRJGRVXNJI-YUMQZZPRSA-N Leu-Cys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)NCC(O)=O IASQBRJGRVXNJI-YUMQZZPRSA-N 0.000 claims description 4
QCWJKJLNCFEVPQ-WHFBIAKZSA-N Asn-Gln Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O QCWJKJLNCFEVPQ-WHFBIAKZSA-N 0.000 claims description 3
ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 3
210000004899 c-terminal region Anatomy 0.000 claims description 3
102100032378 Carboxypeptidase E Human genes 0.000 claims description 2
108010058255 Carboxypeptidase H Proteins 0.000 claims description 2
YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 claims description 2
FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
108010040443 aspartyl-aspartic acid Proteins 0.000 claims 1
238000006467 substitution reaction Methods 0.000 abstract description 23
239000000539 dimer Substances 0.000 abstract description 13
229920000642 polymer Polymers 0.000 abstract description 9
230000007935 neutral effect Effects 0.000 abstract description 7
229940123452 Rapid-acting insulin Drugs 0.000 abstract 1
108010026951 Short-Acting Insulin Proteins 0.000 abstract 1
239000013612 plasmid Substances 0.000 description 44
239000012634 fragment Substances 0.000 description 25
108090000623 proteins and genes Proteins 0.000 description 21
239000000203 mixture Substances 0.000 description 20
239000000243 solution Substances 0.000 description 18
230000009466 transformation Effects 0.000 description 18
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
238000010276 construction Methods 0.000 description 16
240000004808 Saccharomyces cerevisiae Species 0.000 description 15
108020004414 DNA Proteins 0.000 description 12
230000027455 binding Effects 0.000 description 10
230000000694 effects Effects 0.000 description 10
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
230000035772 mutation Effects 0.000 description 8
239000000600 sorbitol Substances 0.000 description 8
239000011701 zinc Substances 0.000 description 8
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000000047 product Substances 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
238000005119 centrifugation Methods 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
102000053602 DNA Human genes 0.000 description 4
108020004682 Single-Stranded DNA Proteins 0.000 description 4
108700005078 Synthetic Genes Proteins 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000000178 monomer Substances 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
238000010254 subcutaneous injection Methods 0.000 description 4
239000007929 subcutaneous injection Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
239000008272 agar Substances 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
238000005571 anion exchange chromatography Methods 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
108010052305 exodeoxyribonuclease III Proteins 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000003914 insulin secretion Effects 0.000 description 3
231100000219 mutagenic Toxicity 0.000 description 3
230000003505 mutagenic effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
108020004638 Circular DNA Proteins 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241001524679 Escherichia virus M13 Species 0.000 description 2
101001027925 Homo sapiens Metastasis-associated protein MTA1 Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
102100037517 Metastasis-associated protein MTA1 Human genes 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
101000993800 Sus scrofa Insulin Proteins 0.000 description 2
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000006240 deamidation Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
108010023063 Bacto-peptone Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical group OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
101500025353 Homo sapiens Insulin A chain Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
108010092217 Long-Acting Insulin Proteins 0.000 description 1
102000016261 Long-Acting Insulin Human genes 0.000 description 1
229940100066 Long-acting insulin Drugs 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
PNVLWFYAPWAQMU-CIUDSAMLSA-N Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)C(C)C PNVLWFYAPWAQMU-CIUDSAMLSA-N 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
239000001639 calcium acetate Substances 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000000499 gel Substances 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
239000010439 graphite Substances 0.000 description 1
238000003505 heat denaturation Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
108010033606 insulin dimers Proteins 0.000 description 1
229950004152 insulin human Drugs 0.000 description 1
210000002660 insulin-secreting cell Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000008188 pellet Substances 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000005373 porous glass Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000007261 sc medium Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229940087562 sodium acetate trihydrate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
YZYKBQUWMPUVEN-UHFFFAOYSA-N zafuleptine Chemical compound OC(=O)CCCCCC(C(C)C)NCC1=CC=C(F)C=C1 YZYKBQUWMPUVEN-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CS866310A 1985-08-30 1986-08-29 Process for preparing insulin analogs CS275613B6 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK395685A DK395685D0 (da)	1985-08-30	1985-08-30	Peptider
DK467785A DK467785D0 (da)	1985-10-14	1985-10-14	Peptider

Publications (2)

Publication Number	Publication Date
CS8606310A2 CS8606310A2 (en)	1990-09-12
CS275613B6 true CS275613B6 (en)	1992-03-18

Family

ID=26067291

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS866310A CS275613B6 (en)	1985-08-30	1986-08-29	Process for preparing insulin analogs

Country Status (25)

Country	Link
US (1)	US5618913A (fr)
EP (1)	EP0214826B1 (fr)
JP (1)	JP2662390B2 (fr)
KR (1)	KR940000756B1 (fr)
CN (1)	CN1029977C (fr)
AR (1)	AR241801A1 (fr)
AT (1)	ATE113061T1 (fr)
AU (1)	AU593274B2 (fr)
CA (1)	CA1306212C (fr)
CS (1)	CS275613B6 (fr)
DD (1)	DD268976A5 (fr)
DE (2)	DE3650101T2 (fr)
ES (1)	ES2001624A6 (fr)
FI (1)	FI102182B (fr)
GR (1)	GR862233B (fr)
HU (1)	HU206518B (fr)
IE (1)	IE66138B1 (fr)
IL (1)	IL79887A (fr)
LU (1)	LU90484I2 (fr)
NL (1)	NL990042I2 (fr)
NO (2)	NO177009C (fr)
NZ (1)	NZ217406A (fr)
PH (1)	PH25772A (fr)
PT (1)	PT83278B (fr)
YU (2)	YU46023B (fr)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK437786D0 (da) *	1986-09-12	1986-09-12	Nordisk Gentofte	Insulinprecursorer
WO1988006599A1 (fr) *	1987-02-25	1988-09-07	Novo Industri A/S	Nouveaux derives d'insuline
US4992418A (en) *	1987-07-17	1991-02-12	Mount Sinai School Of Medicine	Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
US4992417A (en) *	1987-07-17	1991-02-12	Mount Sinai School Of Medicine	Superactive human insulin analogues
CA1340772C (fr)	1987-12-30	1999-09-28	Patricia Tekamp-Olson	Expression et secretion de proteines heterologues dans une levure au moyen de sequences leader tronquees du facteur alpha
ATE93238T1 (de) *	1988-07-20	1993-09-15	Novo Nordisk As	Menschliche insulinanalage und zubereitungen daraus.
DE3837825A1 (de) *	1988-11-08	1990-05-10	Hoechst Ag	Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5716927A (en) *	1988-12-23	1998-02-10	Novo Nordisk A/S	Insulin analogs having a modified B-chain
HUT56857A (en) *	1988-12-23	1991-10-28	Novo Nordisk As	Human insulin analogues
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
AU631868B2 (en) *	1989-04-20	1992-12-10	Mount Sinai School Of Medicine Of The City University Of New York, The	Hepatospecific insulin analogues
US5208217A (en) *	1989-04-20	1993-05-04	Mount Sinai School Of Medicine Of The City University Of New York	Hepatospecific insulin analogues
DK155690D0 (da) *	1990-06-28	1990-06-28	Novo Nordisk As	Nye peptider
DK158390D0 (da) *	1990-07-02	1990-07-02	Novo Nordisk As	Nye peptider
DK10191D0 (da) *	1991-01-22	1991-01-22	Novo Nordisk As	Hidtil ukendte peptider
DK33591D0 (fr) *	1991-02-27	1991-02-27	Novo Nordisk As
NO922376L (no) *	1991-06-21	1992-12-22	Lilly Co Eli	Insulinanaloger
JPH08504820A (ja) *	1992-12-18	1996-05-28	イーライ・リリー・アンド・カンパニー	インシュリン類似体
DK72793D0 (da) *	1993-06-21	1993-06-21	Novo Nordisk As	Nyt produkt
JP2837956B2 (ja) *	1993-06-21	1998-12-16	ノボノルディスクアクティーゼルスカブ	Ａｓｐ▲上Ｂ２８▼インスリン結晶
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5504188A (en) *	1994-06-16	1996-04-02	Eli Lilly And Company	Preparation of stable zinc insulin analog crystals
US5547929A (en) *	1994-09-12	1996-08-20	Eli Lilly And Company	Insulin analog formulations
AU3562195A (en) *	1994-10-04	1996-04-26	Novo Nordisk A/S	Preparations containing aspb28 human insulin and nicotinamide
US5597893A (en) *	1994-10-31	1997-01-28	Eli Lilly And Company	Preparation of stable insulin analog crystals
US5693609A (en) *	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
US5646242A (en)	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
YU18596A (sh) *	1995-03-31	1998-07-10	Eli Lilly And Company	Analogne formulacije monomernog insulina
US5631347A (en) *	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
US5700904A (en) *	1995-06-07	1997-12-23	Eli Lilly And Company	Preparation of an acylated protein powder
PT921812E (pt) *	1996-06-20	2002-04-29	Novo Nordisk As	Preparacoes de insulina contendo um halogenuro
ZA984697B (en) *	1997-06-13	1999-12-01	Lilly Co Eli	Stable insulin formulations.
DE19726167B4 (de)	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
SV1998000125A (es)	1997-10-24	1999-05-24	Lilly Co Eli	Composiciones de insulina insoluble ref. x-11232
US6531448B1 (en)	1997-12-23	2003-03-11	Eli Lilly And Company	Insoluble compositions for controlling blood glucose
NZ506447A (en) *	1998-02-23	2002-11-26	Neurocrine Biosciences Inc	Peptide analogues of insulin with alanine substitutions and pharmaceutical use
DE19825447A1 (de) *	1998-06-06	1999-12-09	Hoechst Marion Roussel De Gmbh	Neue Insulinanaloga mit erhöhter Zinkbildung
AUPP609198A0 (en) *	1998-09-22	1998-10-15	Curtin University Of Technology	Use of non-peptidyl compounds for the treatment of insulin related ailments
US6933272B1 (en)	1998-09-22	2005-08-23	Erik Helmerhorst	Use of non-peptidyl compounds for the treatment of insulin related ailments
PT1141014E (pt)	1999-01-06	2005-04-29	Genentech Inc	Variante mutante do factor de crescimento semelhante a insulina (igf-i)
DE60042550D1 (de)	1999-01-06	2009-08-27	Genentech Inc	Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
US6746853B1 (en) *	1999-05-19	2004-06-08	Xencor, Inc.	Proteins with insulin-like activity useful in the treatment of diabetes
CN1125081C (zh) *	1999-09-08	2003-10-22	中国科学院上海生物化学研究所	重组天然和新型人胰岛素及其制备方法
US7022674B2 (en) *	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
JP2003528149A (ja)	2000-03-24	2003-09-24	ジェネンテック・インコーポレーテッド	軟骨性疾患の治療のためのインスリンの使用
AU2001254621A1 (en) *	2000-05-05	2001-11-20	K.U. Leuven R And D	Critical illness neuropathy
ES2301547T3 (es)	2000-05-16	2008-07-01	Genentech, Inc.	Tratamiento de trastornos del cartilago.
AR025646A1 (es) *	2000-09-13	2002-12-04	Beta Lab Sa	Cepa de levaduras metilotroficas recombinantes productoras de un precursor de insulina, construcciones de adn y metodo para obtener la cepa.
US7202059B2 (en)	2001-02-20	2007-04-10	Sanofi-Aventis Deutschland Gmbh	Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en)	2001-02-20	2009-12-29	Sanofi-Aventis Deutschland Gmbh	Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP1444219A1 (fr)	2001-10-12	2004-08-11	Novo Nordisk A/S	Piperidines substituees et leur utilisation dans le traitement de maladies liees au recepteur histaminique h3
ATE464390T1 (de)	2001-11-19	2010-04-15	Novo Nordisk As	Verfahren zur herstellung von insulinverbindungen
GB0206792D0 (en)	2002-03-22	2002-05-01	Leuven K U Res & Dev	Normoglycemia
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en)	2002-10-29	2007-03-20	Sanofi-Aventis Deutschland Gmbh	Crystals of insulin analogs and processes for their preparation
US7871607B2 (en) *	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1618090A1 (fr)	2003-04-11	2006-01-25	Novo Nordisk A/S	COMPOSES ACTIFS DE LA 11ß-HYDROXYSTEROIDE DESHYDROGENASE DE TYPE 1
EP1641616B1 (fr)	2003-06-27	2011-04-13	Novo Nordisk A/S	Contenant a fort effet de barriere contre l'humidite pour compositions medicales liquides
US20060183667A1 (en) *	2003-07-11	2006-08-17	Novo Nordisk A/S	Stabilised insulin compositions
EP1644411A2 (fr) *	2003-07-11	2006-04-12	Novo Nordisk A/S	Compositions d'insuline stabilisee
SI1648933T1 (sl) *	2003-07-25	2010-01-29	Conjuchem Biotechnologies Inc	Dolgo delujoäś inzulinski derivat in metoda zanj
KR101159559B1 (ko)	2003-08-05	2012-06-26	노보 노르디스크 에이/에스	신규의 인슐린 유도체
KR101186851B1 (ko)	2003-08-05	2012-10-02	노보 노르디스크 에이/에스	신규의 인슐린 유도체
WO2005046716A1 (fr) *	2003-11-13	2005-05-26	Novo Nordisk A/S	Compositions pharmaceutiques solubles destinées à l'administration parentérale comprenant un peptide glp-1 et un peptide d'insuline à temps d'action de courte durée, utiles pour le traitement du diabète et de la boulimie
US20060287221A1 (en) *	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
DK3300721T4 (da)	2003-11-20	2025-03-03	Novo Nordisk As	Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
JP5697831B2 (ja)	2003-12-03	2015-04-08	ノヴォノルディスクアー／エス	単鎖インシュリン
CN1898087A (zh)	2003-12-22	2007-01-17	诺沃挪第克公司	用于储存药物液体的透明、柔性、不可渗透的塑料容器
EP2368579A1 (fr)	2004-01-21	2011-09-28	Novo Nordisk Health Care AG	Conjugaison au moyen de transglutaminase de peptides
MX2007000883A (es)	2004-07-19	2007-04-02	Biocon Ltd	Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
CN101115900B (zh)	2004-11-04	2012-03-07	亨特道格拉斯有限公司	用于建筑开口的单轨道层叠板体遮蔽件
US7833513B2 (en)	2004-12-03	2010-11-16	Rhode Island Hospital	Treatment of Alzheimer's Disease
EP2256130B1 (fr)	2005-02-02	2013-09-25	Novo Nordisk A/S	Nouveaux dérivés d'insuline
JP5410020B2 (ja)	2005-02-02	2014-02-05	ノヴォノルディスクアー／エス	インスリン誘導体
MX2007015675A (es)	2005-07-04	2008-02-20	Novo Nordisk As	Antagonistas del receptor de histamina h3.
WO2007015805A1 (fr)	2005-07-20	2007-02-08	Eli Lilly And Company	Composés joints en position 1-amino
CN101243190B (zh)	2005-08-16	2015-05-13	诺沃-诺迪斯克有限公司	制备成熟胰岛素多肽的方法
PT1926749E (pt)	2005-09-14	2011-09-29	Sanofi Aventis Deutschland	Clivagem de precursores de insulinas por uma variante de tripsina
WO2007123581A1 (fr)	2005-11-17	2007-11-01	Eli Lilly And Company	Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
US8343914B2 (en) *	2006-01-06	2013-01-01	Case Western Reserve University	Fibrillation resistant proteins
US20090069216A1 (en) *	2006-02-21	2009-03-12	Novo Nordisk A/S	Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
DE602007009496D1 (de)	2006-02-27	2010-11-11	Novo Nordisk As	Insulinderivate
ES2397659T3 (es)	2006-03-15	2013-03-08	Novo Nordisk A/S	Mezclas de amilina e insulina
CN101410385B (zh)	2006-03-28	2011-08-24	高点制药有限责任公司	具有组胺h3受体活性的苯并噻唑类
JP5118692B2 (ja)	2006-04-24	2013-01-16	イーライリリーアンドカンパニー	１１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロヘキシル置換ピロリジノン
US8796205B2 (en)	2006-05-09	2014-08-05	Novo Nordisk A/S	Insulin derivative
EP2015770B1 (fr)	2006-05-09	2012-09-26	Novo Nordisk A/S	Dérivé d'insuline
KR20090040259A (ko)	2006-05-29	2009-04-23	하이 포인트 파마슈티칼스, 엘엘씨	3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 ｈ3 수용체 안타고니스트로서의 용도
JP2009539778A (ja) *	2006-06-08	2009-11-19	ダイアベコアメディカルインコーポレイテッド	インスリンオリゴマー誘導体
DE102006031962A1 (de)	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Amidiertes Insulin Glargin
DE102006031955A1 (de) *	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
EP2049149B1 (fr)	2006-07-31	2015-04-15	Novo Nordisk A/S	Insulines pegylées à extensions
EP2404934A1 (fr) *	2006-09-22	2012-01-11	Novo Nordisk A/S	Analogues d'insuline résistants à la protéase
ES2554773T3 (es) *	2006-10-04	2015-12-23	Case Western Reserve University	Insulina y análogos de la insulina resistentes a la fibrilación
WO2008049711A1 (fr) *	2006-10-27	2008-05-02	Novo Nordisk A/S	Insuline à peptide ajouté
US20120214963A1 (en) *	2011-02-23	2012-08-23	Elona Biotechnologies	Aspart proinsulin compositions and methods of producing aspart insulin analogs therefrom
US10100098B2 (en)	2006-12-13	2018-10-16	Stelis Biopharma Private Limited	Insulin production methods and proinsulin constructs
ES2563038T3 (es)	2007-04-30	2016-03-10	Novo Nordisk A/S	Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
WO2008139496A1 (fr) *	2007-05-16	2008-11-20	Bigtec Private Limited	Insuline humaine de recombinaison et méthode associée
US20100190706A1 (en)	2007-06-01	2010-07-29	Novo Nordisk A/S	Stable Non-Aqueous Pharmaceutical Compositions
EP2164466A1 (fr)	2007-06-01	2010-03-24	Novo Nordisk A/S	Préconcentrés spontanément dispersibles comprenant un médicament peptidique dans un excipient solide ou semi-solide
WO2008152106A1 (fr)	2007-06-13	2008-12-18	Novo Nordisk A/S	Formulation pharmaceutique contenant un dérivé d'insuline
EP2178911A2 (fr) *	2007-08-13	2010-04-28	Novo Nordisk A/S	Analogues de l'insuline à action rapide
ES2558930T3 (es)	2007-08-13	2016-02-09	Novo Nordisk A/S	Análogos de la insulina de acción rápida
CN101784563B (zh)	2007-08-15	2015-02-04	诺沃-诺迪斯克有限公司	具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素
KR20100053561A (ko)	2007-08-15	2010-05-20	노보 노르디스크 에이/에스	아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
US8946148B2 (en)	2007-11-20	2015-02-03	Ambrx, Inc.	Modified insulin polypeptides and their uses
PL2229407T3 (pl)	2008-01-09	2017-06-30	Sanofi-Aventis Deutschland Gmbh	Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
MX2010009850A (es)	2008-03-18	2010-09-30	Novo Nordisk As	Analogos de insulina acilados y etabilizados contra proteasas.
ES2563553T3 (es)	2008-04-01	2016-03-15	Novo Nordisk A/S	Conjugados de insulina-albúmina
US8993516B2 (en) *	2008-04-14	2015-03-31	Case Western Reserve University	Meal-time insulin analogues of enhanced stability
CN102065885A (zh) *	2008-04-22	2011-05-18	卡斯西部储备大学	同种型特异性的胰岛素类似物
TWI394580B (zh)	2008-04-28	2013-05-01	Halozyme Inc	超快起作用胰島素組成物
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
KR20120129875A (ko)	2008-07-31	2012-11-28	케이스 웨스턴 리저브 유니버시티	염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en)	2008-07-31	2015-12-01	Case Western Reserve University	Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20110059602A (ko)	2008-08-07	2011-06-02	바이오콘 리미티드	인슐린 화합물의 제조방법
DE102008051834A1 (de)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
EP3228320B1 (fr)	2008-10-17	2019-12-18	Sanofi-Aventis Deutschland GmbH	Combinaison d'une insuline et d'un antagoniste glp 1
DE102009038210A1 (de)	2009-08-20	2011-03-03	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de)	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
CA2738615A1 (fr)	2008-10-30	2010-05-06	Novo Nordisk A/S	Traitement du diabete a l'aide d'injections d'insuline avec une frequence inferieure a une injection par jour
MX2011005037A (es)	2008-11-21	2011-06-16	High Point Pharmaceuticals Llc	Compuestos de adamantilo benzamida.
US9018190B2 (en)	2009-03-27	2015-04-28	Adocia	Functionalized oligosaccharides
FR2943538B1 (fr)	2009-03-27	2011-05-20	Adocia	Formulation a action rapide d'insuline recombinante humaine
EP3202394A1 (fr)	2009-07-06	2017-08-09	Sanofi-Aventis Deutschland GmbH	Préparations aqueuses de l´insuline contenant de la méthionine
EP2451471A1 (fr)	2009-07-06	2012-05-16	Sanofi-Aventis Deutschland GmbH	Préparations d'insuline à effet retard
US20120241356A1 (en)	2009-07-06	2012-09-27	Sanofi-Aventis Deutschland Gmbh	Heat- and vibration-stable insulin preparations
AU2010277559B2 (en)	2009-07-31	2016-08-11	Sanofi-Aventis Deutschland Gmbh	Prodrugs comprising an insulin linker conjugate
PT2459171T (pt)	2009-07-31	2017-08-16	Sanofi Aventis Deutschland	Composição de insulina de atuação longa
US8399407B2 (en) *	2009-09-17	2013-03-19	Case Western Reserve University	Non-standard insulin analogues
PT2554183T (pt)	2009-11-13	2018-07-09	Sanofi Aventis Deutschland	Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
PE20121316A1 (es)	2009-11-13	2012-10-05	Sanofi Aventis Deutschland	Composicion farmaceutica que comprende un agonista de glp-1 y metionina
US8637096B2 (en)	2009-12-04	2014-01-28	Curtis C. Stojan	Compositions and method for enhancing insulin activity
NZ600477A (en)	2009-12-11	2014-07-25	Univ Case Western Reserve	Insulin analogues with chlorinated amino acids
EP2359843A1 (fr)	2010-01-21	2011-08-24	Sanofi	Composition pharmaceutique pour le traitement d'un syndrome métabolique
UY33326A (es)	2010-04-14	2011-12-01	Sanofi Aventis	Conjugados de insulina-sirna
EP2569002B1 (fr)	2010-05-10	2016-10-26	Novo Nordisk A/S	Procédé de préparation de complexes d'insuline et de zinc
WO2011159895A2 (fr)	2010-06-16	2011-12-22	Indiana University Research And Technology Corporation	Agonistes de l'insuline à une seule chaîne très actifs au niveau du récepteur à l'insuline
WO2011161125A1 (fr)	2010-06-23	2011-12-29	Novo Nordisk A/S	Dérivés d'insuline contenant des liaisons disulfure supplémentaires
EP3572091B1 (fr)	2010-08-17	2023-12-13	Ambrx, Inc.	Polypeptides de relaxine modifiés et leurs utilisations
US20140148384A1 (en)	2010-08-30	2014-05-29	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2438930A1 (fr)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Promédicaments comprenant un conjugué de liaison d'exendine
SI2632478T1 (sl)	2010-10-27	2019-11-29	Novo Nordisk As	Zdravljenje sladkorne bolezni z uporabo inzulinskih injekcij, ki se dajejo v različnih injicirnih intervalih
JP6049625B2 (ja)	2010-10-27	2016-12-21	ノヴォノルディスクアー／エス	様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US20130331320A1 (en)	2010-12-14	2013-12-12	Novo Nordisk A/S	Fast-acting insulin in combination with long-acting insulin
JP6110312B2 (ja) *	2011-02-01	2017-04-05	ノヴォノルディスクアー／エス	インスリンの精製
EP2670368A4 (fr)	2011-02-03	2015-04-15	Pharmedica Ltd	Nouveaux films à dissolution orale pour administration d'insuline, pour traitement du diabète
WO2012115638A1 (fr)	2011-02-23	2012-08-30	Elona Biotechnologies	Compositions de pro-insuline glargine et procédés de production d'analogues de l'insuline glargine à partir de celles-ci
WO2012115637A1 (fr) *	2011-02-23	2012-08-30	Elona Biotechnologies	Compositions de pro-insuline aspart et procédés de production d'analogues de l'insuline aspart
WO2012123519A2 (fr)	2011-03-15	2012-09-20	Novo Nordisk A/S	Analogues de l'insuline humaine et dérivés comprenant des substitutions de cystéine
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130011378A1 (en)	2011-06-17	2013-01-10	Tzung-Horng Yang	Stable formulations of a hyaluronan-degrading enzyme
EP2548570A1 (fr)	2011-07-19	2013-01-23	Sanofi	Composition pharmaceutique pour le traitement d'un syndrome métabolique
CN108079281A (zh)	2011-08-29	2018-05-29	赛诺菲-安万特德国有限公司	用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130231281A1 (en)	2011-11-02	2013-09-05	Adocia	Rapid acting insulin formulation comprising an oligosaccharide
EP2784085A4 (fr)	2011-12-15	2015-07-08	Shanghai Hengrui Pharm Co Ltd	Analogue d'insuline humaine et son dérivé acylé
US9573987B2 (en)	2011-12-20	2017-02-21	Indiana University Research And Technology Corporation	CTP-based insulin analogs for treatment of diabetes
KR20150002777A (ko)	2012-04-11	2015-01-07	노보 노르디스크 에이/에스	인슐린 제제
WO2013164375A1 (fr)	2012-05-01	2013-11-07	Novo Nordisk A/S	Composition pharmaceutique
WO2013173923A1 (fr)	2012-05-25	2013-11-28	Diamedica, Inc.	Formulations de kallikréine 1 de tissu humain pour l'administration parentérale et procédés associés
EP2854841B1 (fr)	2012-06-04	2017-02-22	Diamedica Inc.	Isoformes de glycosylation de la kallikréine-1 tissulaire d'origine humaine
CN108383902A (zh)	2012-09-26	2018-08-10	印第安纳大学研究及科技有限公司	胰岛素类似物二聚体
KR20150082640A (ko)	2012-11-13	2015-07-15	아도시아	치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
JP6735561B2 (ja)	2012-12-03	2020-08-05	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
US9867869B2 (en)	2012-12-12	2018-01-16	Massachusetts Institute Of Technology	Insulin derivatives for diabetes treatment
MX360420B (es)	2012-12-19	2018-10-31	Wockhardt Ltd	Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
MX2015006997A (es)	2012-12-26	2015-09-23	Wockhardt Ltd	Composicion farmaceutica.
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2014158900A1 (fr)	2013-03-14	2014-10-02	Indiana University Research And Technology Corporation	Conjugués d'insuline-incrétine
WO2014177623A1 (fr)	2013-04-30	2014-11-06	Novo Nordisk A/S	Schéma d'administration d'un nouveau type
IN2013MU03124A (fr)	2013-09-30	2015-07-31	Wockhardt Ltd
AU2014333979B2 (en)	2013-10-07	2018-02-15	Novo Nordisk A/S	Novel derivative of an insulin analogue
RU2016132340A (ru)	2014-01-09	2018-02-14	Санофи	Стабилизированные фармацевтические составы на основе инсулина аспарта
CN105899191B (zh)	2014-01-09	2020-06-16	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
KR20160104724A (ko)	2014-01-09	2016-09-05	사노피	인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
US9795678B2 (en)	2014-05-14	2017-10-24	Adocia	Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr)	2014-05-14	2018-08-31	Adocia	Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9656017B2 (en)	2014-06-20	2017-05-23	Howard E. Greene	Infusion delivery devices and methods
WO2016001862A1 (fr)	2014-07-04	2016-01-07	Wockhardt Limited	Formulations à libération prolongée d'insulines
ES2822994T3 (es)	2014-09-24	2021-05-05	Univ Indiana Res & Tech Corp	Conjugados de incretina-insulina
CN107108716A (zh)	2014-10-06	2017-08-29	卡斯西部储备大学	双相性单链胰岛素类似物
SG10201809457YA (en)	2014-11-21	2018-11-29	Merck Sharp & Dohme	Insulin receptor partial agonists
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TW201630622A (zh)	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
CN105884879A (zh) *	2015-01-26	2016-08-24	漳州博欣生物技术有限公司	一种胰岛素类似物的化学合成方法
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
CA2996455A1 (fr)	2015-08-25	2017-03-02	Novo Nordisk A/S	Nouveaux derives d'insuline et leurs utilisations medicales
JO3749B1 (ar)	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr)	2015-11-16	2019-05-31	Adocia	Composition a action rapide d'insuline comprenant un citrate substitue
WO2017180988A2 (fr)	2016-04-15	2017-10-19	Indiana University Research And Technology Corporation	Optimisation peptidique à fgf21 c-terminal
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
EP3922260A3 (fr)	2016-05-24	2022-06-15	Merck Sharp & Dohme Corp.	Agonistes partiels du récepteur de l'insuline et analogues du glp-1
WO2017205309A1 (fr)	2016-05-25	2017-11-30	Merck Sharp & Dohme Corp.	Agonistes partiels du récepteur de l'insuline
TWI747929B (zh)	2016-08-02	2021-12-01	大陸商江蘇恆瑞醫藥股份有限公司	一種人胰島素或其類似物的醯化衍生物
AU2017334290B2 (en)	2016-09-29	2023-04-20	Arecor Limited	Novel formulations
MA49116A (fr)	2016-12-16	2020-03-25	Novo Nordisk As	Compositions pharmaceutiques contenant de l'insuline
AU2018230478B2 (en)	2017-03-09	2025-01-23	Diamedica Inc.	Dosage forms of tissue kallikrein 1
GB201707187D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707188D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707189D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
WO2018222787A1 (fr)	2017-06-01	2018-12-06	Eli Lilly And Company	Compositions d'insuline à action rapide
PE20211264A1 (es)	2017-08-17	2021-07-15	Novo Nordisk As	Analogos de insulina acilados novedosos y usos de estos
US20210113763A1 (en)	2018-04-04	2021-04-22	Arecor Limited	Medical infusion pump system for the delivery of an insulin compound
IL277721B2 (en)	2018-04-04	2024-03-01	Arecor Ltd	Medical infusion pump system for the delivery of an insulin compound
WO2019193349A1 (fr)	2018-04-04	2019-10-10	Arecor Limited	Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
US12325732B2 (en)	2018-09-12	2025-06-10	Amphastar Nanjing Pharmaceuticals Inc	Pro-insulin aspart structure and method for preparing insulin aspart
KR20200082618A (ko)	2018-12-31	2020-07-08	주식회사 폴루스	인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
CN114096269B (zh)	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂
FI4073097T3 (fi) *	2019-12-11	2024-08-13	Novo Nordisk As	Uusia insuliinianalogeja ja niiden käyttötapoja
CN119060162A (zh)	2019-12-30	2024-12-03	甘李药业股份有限公司	长效glp-1化合物
CN118772259A (zh)	2019-12-30	2024-10-15	甘李药业股份有限公司	胰岛素衍生物
GB202004814D0 (en)	2020-04-01	2020-05-13	Arecor Ltd	Novel formulations
EP4471053A1 (fr)	2022-01-28	2024-12-04	Gan & Lee Pharmaceuticals Co., Ltd.	Insuline acylée
AR129357A1 (es)	2022-05-18	2024-08-14	Protomer Tech Inc	Compuestos aromáticos que contienen boro y análogos de insulina relacionados

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2252157C3 (de) *	1972-10-25	1976-03-18	Hoechst Ag	Zwischenprodukte zur herstellung von insulin, insulin-analogen und -derivaten und verfahren zur herstellung von insulin, insulin analogen und derivaten
US4652525A (en) *	1978-04-19	1987-03-24	The Regents Of The University Of California	Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4565785A (en) *	1978-06-08	1986-01-21	The President And Fellows Of Harvard College	Recombinant DNA molecule
US4411994A (en) *	1978-06-08	1983-10-25	The President And Fellows Of Harvard College	Protein synthesis
JPS55138391A (en) *	1979-04-13	1980-10-29	Shionogi & Co Ltd	New synthetic method of peptide derivative
US4343898A (en) *	1980-02-11	1982-08-10	Novo Industri A/S	Process for preparing esters of human insulin
US4340674A (en) *	1980-05-05	1982-07-20	The Upjohn Company	Cointegrate plasmids and their construction from plasmids of Escherichia and Streptomyces
US4351901A (en) *	1980-03-24	1982-09-28	Cetus Corporation	Method for single nucleotide alteration
DK319780A (da) *	1980-07-24	1982-01-25	Forenede Bryggerier As	Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
ZA824218B (en) *	1981-06-29	1983-04-27	Cetus Corp	Plasmid for producing human insulin
DK58285D0 (da) *	1984-05-30	1985-02-08	Novo Industri As	Peptider samt fremstilling og anvendelse deraf
US5008241A (en) *	1985-03-12	1991-04-16	Novo Nordisk A/S	Novel insulin peptides
DK129385A (da) *	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
DK134189D0 (da) *	1989-03-20	1989-03-20	Nordisk Gentofte	Insulinforbindelser
US5559094A (en) *	1994-08-02	1996-09-24	Eli Lilly And Company	AspB1 insulin analogs

1986
- 1986-08-22 PH PH34177A patent/PH25772A/en unknown
- 1986-08-26 YU YU148486A patent/YU46023B/sh unknown
- 1986-08-28 CN CN86106574A patent/CN1029977C/zh not_active Expired - Lifetime
- 1986-08-29 AU AU62066/86A patent/AU593274B2/en not_active Expired
- 1986-08-29 DD DD29398186A patent/DD268976A5/de unknown
- 1986-08-29 IL IL79887A patent/IL79887A/xx not_active IP Right Cessation
- 1986-08-29 FI FI863512A patent/FI102182B/fi not_active IP Right Cessation
- 1986-08-29 CA CA000517255A patent/CA1306212C/fr not_active Expired - Lifetime
- 1986-08-29 KR KR1019860007225A patent/KR940000756B1/ko not_active Expired - Lifetime
- 1986-08-29 DE DE3650101T patent/DE3650101T2/de not_active Expired - Lifetime
- 1986-08-29 DE DE2000175008 patent/DE10075008I2/de active Active
- 1986-08-29 AT AT86306721T patent/ATE113061T1/de active
- 1986-08-29 NZ NZ217406A patent/NZ217406A/xx unknown
- 1986-08-29 IE IE231786A patent/IE66138B1/en not_active IP Right Cessation
- 1986-08-29 JP JP61201906A patent/JP2662390B2/ja not_active Expired - Lifetime
- 1986-08-29 HU HU863754A patent/HU206518B/hu unknown
- 1986-08-29 NO NO863474A patent/NO177009C/no not_active IP Right Cessation
- 1986-08-29 GR GR862233A patent/GR862233B/el unknown
- 1986-08-29 EP EP86306721A patent/EP0214826B1/fr not_active Expired - Lifetime
- 1986-08-29 ES ES8601507A patent/ES2001624A6/es not_active Expired
- 1986-08-29 US US06/901,821 patent/US5618913A/en not_active Expired - Lifetime
- 1986-08-29 CS CS866310A patent/CS275613B6/cs not_active IP Right Cessation
- 1986-08-29 PT PT83278A patent/PT83278B/pt unknown
- 1986-08-29 AR AR86305098A patent/AR241801A1/es active
1988
- 1988-01-11 YU YU4188A patent/YU46857B/sh unknown
1999
- 1999-12-06 NL NL990042C patent/NL990042I2/nl unknown
- 1999-12-21 LU LU90484C patent/LU90484I2/fr unknown
2000
- 2000-07-21 NO NO2000005C patent/NO2000005I1/no unknown

Also Published As

Publication number	Publication date
CN86106574A (zh)	1988-08-03
CA1306212C (fr)	1992-08-11
ATE113061T1 (de)	1994-11-15
EP0214826A2 (fr)	1987-03-18
JPS6253999A (ja)	1987-03-09
EP0214826A3 (en)	1987-06-03
HUT42526A (en)	1987-07-28
AU6206686A (en)	1987-03-05
CN1029977C (zh)	1995-10-11
YU46857B (sh)	1994-06-24
NL990042I2 (nl)	2000-03-01
PH25772A (en)	1991-10-18
DD268976A5 (de)	1989-06-14
LU90484I2 (fr)	2000-02-21
NO177009B (no)	1995-03-27
FI102182B1 (fi)	1998-10-30
DE10075008I1 (de)	2000-05-18
FI863512A0 (fi)	1986-08-29
AU593274B2 (en)	1990-02-08
YU148486A (en)	1991-04-30
PT83278A (en)	1986-09-01
US5618913A (en)	1997-04-08
KR870002165A (ko)	1987-03-30
IL79887A (en)	1991-11-21
IL79887A0 (en)	1986-11-30
NO863474L (no)	1987-03-02
DE3650101D1 (de)	1994-11-24
PT83278B (pt)	1989-03-30
DE3650101T2 (de)	1995-02-23
IE862317L (en)	1987-02-28
NL990042I1 (nl)	2000-02-01
ES2001624A6 (es)	1988-06-01
KR940000756B1 (ko)	1994-01-29
JP2662390B2 (ja)	1997-10-08
EP0214826B1 (fr)	1994-10-19
GR862233B (en)	1986-12-31
YU46023B (sh)	1992-12-21
DE10075008I2 (de)	2004-10-21
NO2000005I1 (no)	2000-07-21
CS8606310A2 (en)	1990-09-12
NO177009C (no)	1995-07-05
IE66138B1 (en)	1995-12-13
HU206518B (en)	1992-11-30
FI863512L (fi)	1987-03-01
AR241801A1 (es)	1992-12-30
YU4188A (en)	1990-06-30
NZ217406A (en)	1989-05-29
FI102182B (fi)	1998-10-30
NO863474D0 (no)	1986-08-29

Legal Events

Date	Code	Title	Description
2000-06-30	IF00	In force as of 2000-06-30 in czech republic
2009-01-21	MK4A	Patent expired	Effective date: 20060829

Publication	Publication Date	Title
CS275613B6 (en)	1992-03-18	Process for preparing insulin analogs
EP0419504B1 (fr)	1994-01-26	Analogues d'insuline
EP0463072B1 (fr)	1995-01-04	Nouveaux composes d'insuline
AU648670B2 (en)	1994-04-28	A-C-B Proinsulin, method of manufacturing and using same, and intermediates in insulin production
JP2766999B2 (ja)	1998-06-18	プロペプチド
JP4519324B2 (ja)	2010-08-04	共有結合で架橋されたインスリンダイマー
RU2176646C2 (ru)	2001-12-10	Инсулин и его производные с повышенной способностью связывать цинк
CA2006578A1 (fr)	1990-06-23	Analogues de l'insuline humaine
CA2330183C (fr)	2009-10-20	Nouveaux analogues de l'insuline presentant un pouvoir de liaison accru avec le zinc
WO1988010299A1 (fr)	1988-12-29	Procede de preparation d'une proteine ou d'un polypeptide, sequence d'adn codant pour le polypeptide, microorganisme contenant la sequence d'adn et le polypeptide et utilisation du polypeptide comme preparation pharmaceutique
RU2104305C1 (ru)	1998-02-10	Аналоги инсулина человека, способ их получения, раствор для инъекций
WO1992015611A1 (fr)	1992-09-17	Nouveaux derives d'insuline
DK159274B (da)	1990-09-24	Hurtigt virkende human insulinanaloger og injicerbare oploesninger med hurtigt indsaettende virkning indeholdende saadanne insulinanaloger